Stage 2/3 Operable Non Small Cell Lung Cancer
Oncology
Prevalence
6.0 / 100K
Incidence
8.0 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target Stage 2/3 Operable Non Small Cell Lung Cancer?
There are 1 clinical trial targeting Stage 2/3 Operable Non Small Cell Lung Cancer tracked by BioSniper.
What is the prevalence of Stage 2/3 Operable Non Small Cell Lung Cancer?
The estimated prevalence of Stage 2/3 Operable Non Small Cell Lung Cancer is approximately 6.0 per 100,000 population.
Deep-dive into Stage 2/3 Operable Non Small Cell Lung Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis